Literature DB >> 1357602

Production of seizures and brain damage in rats by alpha-dendrotoxin, a selective K+ channel blocker.

G Bagetta1, G Nisticó, J O Dolly.   

Abstract

alpha-Dendrotoxin (Dtx), a snake polypeptide, increases neuronal excitability by blocking certain fast-activating, voltage-dependent K+ channels. Thus, the behavioural, electrocortical (ECoG) and neuropathological effects of Dtx, injected into rat brain areas, were studied. A unilateral injection of 35 pmol of Dtx into the CA1 hippocampal area or the dendate gyrus (DG; upper blade) immediately produced motor and ECoG seizures, followed at 24 h by multi-focal brain damage and significant neuronal loss. Whilst brain damage was seen bilaterally, significant neuronal loss occurred only in regions (CA1, CA3, CA4 and DG) ipsilateral to the site of injection. A lower dose (3.5 pmol) of toxin elicited motor and ECoG seizures but failed to produce brain damage. Seizures were observed 50 min after injecting Dtx (35 pmol) into the amygdala, though significant neuronal loss was not evident. 4-Aminopyridine (100 nmol), given into the CA1 area elicited a similar motor and ECoG pattern to that of Dtx except no brain damage could be seen at 24 h. Systemic pretreatment with antagonists of N-methyl-D-aspartate receptors (MK-801 or CGP 37849) did not protect against the effects typically evoked by injecting Dtx into the CA1 area.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1357602     DOI: 10.1016/0304-3940(92)90851-w

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  15 in total

1.  Identification of the Kv2.1 K+ channel as a major component of the delayed rectifier K+ current in rat hippocampal neurons.

Authors:  H Murakoshi; J S Trimmer
Journal:  J Neurosci       Date:  1999-03-01       Impact factor: 6.167

2.  Protective effect of a new hypothalamic peptide against cobra venom and trauma-induced neuronal injury.

Authors:  A A Galoyan; J S Sarkissian; T K Kipriyan; E J Sarkissian; E A Chavushyan; R M Sulkhanyan; I B Meliksetyan; S S Abrahamyan; Z A Avetisyan; N A Otieva
Journal:  Neurochem Res       Date:  2001-09       Impact factor: 3.996

3.  Comparison of the effects of DC031050, a class III antiarrhythmic agent, on hERG channel and three neuronal potassium channels.

Authors:  Ping Li; Hai-feng Sun; Ping-zheng Zhou; Chao-ying Ma; Guo-yuan Hu; Hua-liang Jiang; Min Li; Hong Liu; Zhao-bing Gao
Journal:  Acta Pharmacol Sin       Date:  2012-05-21       Impact factor: 6.150

4.  Reduced expression of IA channels is associated with post-ischemic seizures.

Authors:  Zhigang Lei; Hui Zhang; Yanling Liang; Zao C Xu
Journal:  Epilepsy Res       Date:  2016-05-19       Impact factor: 3.045

Review 5.  Molecular targets for antiepileptic drug development.

Authors:  Brian S Meldrum; Michael A Rogawski
Journal:  Neurotherapeutics       Date:  2007-01       Impact factor: 7.620

6.  Effects of phrixotoxins on the Kv4 family of potassium channels and implications for the role of Ito1 in cardiac electrogenesis.

Authors:  S Diochot; M D Drici; D Moinier; M Fink; M Lazdunski
Journal:  Br J Pharmacol       Date:  1999-01       Impact factor: 8.739

7.  N-Terminally extended analogues of the K⁺ channel toxin from Stichodactyla helianthus as potent and selective blockers of the voltage-gated potassium channel Kv1.3.

Authors:  Shih C Chang; Redwan Huq; Sandeep Chhabra; Christine Beeton; Michael W Pennington; Brian J Smith; Raymond S Norton
Journal:  FEBS J       Date:  2015-04-23       Impact factor: 5.542

Review 8.  Voltage-gated potassium channels at the crossroads of neuronal function, ischemic tolerance, and neurodegeneration.

Authors:  Niyathi Hegde Shah; Elias Aizenman
Journal:  Transl Stroke Res       Date:  2013-11-19       Impact factor: 6.829

Review 9.  Voltage-gated potassium channels as therapeutic targets.

Authors:  Heike Wulff; Neil A Castle; Luis A Pardo
Journal:  Nat Rev Drug Discov       Date:  2009-12       Impact factor: 84.694

Review 10.  Episodic ataxia type 1: a neuronal potassium channelopathy.

Authors:  Sanjeev Rajakulendran; Stephanie Schorge; Dimitri M Kullmann; Michael G Hanna
Journal:  Neurotherapeutics       Date:  2007-04       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.